- Signaling Pathways
- Cytoskeleton
- Myosin
Myosin
Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).
Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.
Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.
Myosin Isoform Specific Products
All Product Categories
-
Myosin Related Products (105)
Related Products (105)
-
Antibodies (20)
-
Myosin Isoform Comparison
-
Aficamten-d3
0 ImagesCat. No.: HY-W759845Synonyms: CK-274-d3; CK-3773274-d3Aficamten-d3 (CK-274-d3) is deuterium labeled Aficamten. Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Troponin I (104-115)
0 ImagesCat. No.: HY-P2142CAS No.: 98353-69-6Troponin I (104-115) is a polypeptide derived from Troponin I. Troponin I is an inhibitor of Acto-S1-TM ATPase, with an IC50 of 2.25 μM against skeletal muscle Acto-S1-TM ATP enzyme. Troponin I is used in research on muscle contraction-relaxation and restrictive cardiomyopathy. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
(R)-(+)-Blebbistatin O-Benzoate
0 ImagesCat. No.: HY-W776974CAS No.: 1217635-67-0(R)-(+)-Blebbistatin O-Benzoate is a non-muscle myosin II selective inhibitor. (R)-(+)-Blebbistatin O-Benzoate is a derivative of Blebbistatin (HY-13813). (R)-(+)-Blebbistatin O-Benzoate blocks cell membrane bubbling and interferes with directed migration and cytokinesis in vertebrate cells. (R)-(+)-Blebbistatin O-Benzoate inhibits the contraction of mitotic grooves. (R)-(+)-Blebbistatin O-Benzoate can be used as a negative control for (S)-(-)-Blebblastatin. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ML-9 (Standard)
0 ImagesCat. No.: HY-100932RCAS No.: 105637-50-1ML-9 (Standard) is the analytical standard of ML-9 (HY-100932). This product is intended for research and analytical applications. ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Nocarnickelamide B
0 ImagesCat. No.: HY-N15301Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC50s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.